LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microbiologics Introduces SARS-CoV-2 Synthetic RNA for COVID-19 Research

By LabMedica International staff writers
Posted on 18 Mar 2020
Print article
Image: SARS-CoV-2 synthetic RNA Controls (RUO) now available (Photo courtesy of Microbiologics, Inc.)
Image: SARS-CoV-2 synthetic RNA Controls (RUO) now available (Photo courtesy of Microbiologics, Inc.)
Microbiologics, Inc. (Saint Cloud, MN, USA) has prepared synthetic RNA for SARS-CoV-2 to assist in the efforts to monitor the spread of COVID-19.

Microbiologics, a biological products and services provider, partners with healthcare and life science laboratories, manufacturers and suppliers across the world to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology.

The SARS-CoV-2 material is a 1044 nucleotide RNA specific for the SARS-CoV-2 N (nucleocapsid) gene. It contains all three markers (N1, N2 and N3) detected by the CDC Real-Time RT PCR Panel for Detection of 2019 Novel Coronavirus. The RNA material assists in the development of diagnostic assays and the evaluation of the performance of nucleic acid tests for determination of the presence of SARS-COV-2.

The SARS-CoV-2 RNA is available in two different concentrations: 1 x 106 and 1 x 109 genome copies per tube. An IVD version of the product will be added to the Helix EliteTM line from Microbiologics and will be available in the coming weeks.

“We are engaged with our partners and researchers to offer Microbiologics’ virology and molecular biology capabilities to accelerate diagnostics and therapeutic research,” said Brian Beck, Microbiologics’ VP of R&D. “This new RNA material from Microbiologics mimics the viral nucleic acid and provides the exact targets specified by the CDC.”

“In order to effectively respond to the COVID-19 outbreak, scientists need to have confidence in their diagnostic tools to provide rapid, accurate results,” added Beck. “This SARS-CoV-2 material is a critical step forward in our global response against this new strain of coronavirus.”

Related Links:
Microbiologics, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more